These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 23108877

  • 1. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
    Uchiyama T, Sato N, Narita M, Yamahira A, Iwabuchi M, Furukawa T, Sone H, Takahashi M.
    Hematol Oncol; 2013 Sep; 31(3):156-63. PubMed ID: 23108877
    [Abstract] [Full Text] [Related]

  • 2. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
    Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K.
    Leukemia; 2009 Aug; 23(8):1398-405. PubMed ID: 19295545
    [Abstract] [Full Text] [Related]

  • 3. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.
    Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, Lee JJ, Lipton JH.
    Haematologica; 2009 Jan; 94(1):135-9. PubMed ID: 19066329
    [Abstract] [Full Text] [Related]

  • 4. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
    Salih J, Hilpert J, Placke T, Grünebach F, Steinle A, Salih HR, Krusch M.
    Int J Cancer; 2010 Nov 01; 127(9):2119-28. PubMed ID: 20143399
    [Abstract] [Full Text] [Related]

  • 5. Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.
    Nerreter T, Distler E, Köchel C, Einsele H, Herr W, Seggewiss-Bernhardt R.
    Exp Hematol; 2013 Jul 01; 41(7):604-614.e4. PubMed ID: 23466625
    [Abstract] [Full Text] [Related]

  • 6. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.
    Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD.
    Exp Hematol; 2009 Feb 01; 37(2):256-65. PubMed ID: 19056158
    [Abstract] [Full Text] [Related]

  • 7. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
    Chang WC, Hsiao MH, Pattengale PK.
    Nat Immun Cell Growth Regul; 1991 Feb 01; 10(2):57-70. PubMed ID: 1881400
    [Abstract] [Full Text] [Related]

  • 8. Large granular lymphocytosis during dasatinib therapy.
    Qiu ZY, Xu W, Li JY.
    Cancer Biol Ther; 2014 Mar 01; 15(3):247-55. PubMed ID: 24352048
    [Abstract] [Full Text] [Related]

  • 9. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC, Cheng HI, Hsu K, Hsu YN, Kao CW, Chang YF, Lim KH, Chen CG.
    Front Immunol; 2018 Mar 01; 9():3152. PubMed ID: 30705677
    [Abstract] [Full Text] [Related]

  • 10. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
    Paydas S.
    Crit Rev Oncol Hematol; 2014 Feb 01; 89(2):242-7. PubMed ID: 24210599
    [Abstract] [Full Text] [Related]

  • 11. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
    Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S.
    Blood; 2010 Aug 05; 116(5):772-82. PubMed ID: 20413659
    [Abstract] [Full Text] [Related]

  • 12. Dasatinib suppresses in vitro natural killer cell cytotoxicity.
    Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP.
    Blood; 2008 Apr 15; 111(8):4415-6. PubMed ID: 18398058
    [No Abstract] [Full Text] [Related]

  • 13. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.
    Hassold N, Seystahl K, Kempf K, Urlaub D, Zekl M, Einsele H, Watzl C, Wischhusen J, Seggewiss-Bernhardt R.
    Int J Cancer; 2012 Sep 15; 131(6):E916-27. PubMed ID: 22419518
    [Abstract] [Full Text] [Related]

  • 14. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
    D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, Guggino G, Meraviglia S, Caccamo N, Messina A, Salerno A, Di Raimondo F, Vigneri P, Stassi G, Fourniè JJ, Dieli F.
    J Immunol; 2010 Mar 15; 184(6):3260-8. PubMed ID: 20154204
    [Abstract] [Full Text] [Related]

  • 15. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, Mustjoki S, Mohamed H, Shah NP.
    Cancer; 2016 May 01; 122(9):1398-407. PubMed ID: 26998677
    [Abstract] [Full Text] [Related]

  • 16. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
    Okabe S, Tauchi T, Ohyashiki K.
    Clin Cancer Res; 2008 Oct 01; 14(19):6181-6. PubMed ID: 18829496
    [Abstract] [Full Text] [Related]

  • 17. Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.
    Watanabe N, Takaku T, Takeda K, Shirane S, Toyota T, Koike M, Noguchi M, Hirano T, Fujiwara H, Komatsu N.
    Int J Hematol; 2018 Dec 01; 108(6):588-597. PubMed ID: 30151740
    [Abstract] [Full Text] [Related]

  • 18. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 19. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.
    Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, Götz M, Guillaume P, Döhner H, Bunjes D, Schmitt M.
    Exp Hematol; 2008 Oct 01; 36(10):1297-308. PubMed ID: 18619726
    [Abstract] [Full Text] [Related]

  • 20. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M.
    Clin Ther; 2007 Nov 01; 29(11):2289-308. PubMed ID: 18158072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.